Log In
Print this Print this

FP 250

  Manage Alerts
Collapse Summary General Information
Company Formac Pharmaceuticals N.V.
DescriptionCapsule formulation of 33.5 mg fenofibrate formulated with mesoporous silica
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHypercholesterolemia
Indication DetailsTreat hypercholesterolemia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today